118 related articles for article (PubMed ID: 31802944)
1. Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study.
Mu Y; Xing P; Hao X; Wang Y; Li J
Cancer Manag Res; 2019; 11():9243-9251. PubMed ID: 31802944
[TBL] [Abstract][Full Text] [Related]
2. Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study.
Peng D; Shan D; Dai C; Li J; Wang Z; Huang Z; Peng R; Zhao P; Ma X
Cancer Manag Res; 2021; 13():2033-2039. PubMed ID: 33679141
[TBL] [Abstract][Full Text] [Related]
3. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance.
Ma J; Tan SH; Yin DXC; Tran NTA; Tan GS; Lai GGY; Ang MK; Kanesvaran R; Jain A; Rajasekaran T; Tan EH; Lim TKH; Tan DS; Lim DW; Ng QS; Tan WL
Transl Lung Cancer Res; 2023 Apr; 12(4):742-753. PubMed ID: 37197627
[TBL] [Abstract][Full Text] [Related]
4. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced
Zhang D; Liu X; Shen F; Zhao D; Shi Y; Zhang H; Liu J; Gao X; Chen M; Zhao J; Zhong W; Gao J; He M; Liu Y; Yang X; Qin J; Tang Y; Mu X; Gu Y; Zhang S; Chen X; Pang L; Meng Q; Guo Y; Zhang Y; Li W; Xing P; Cheng Y; Xin T; Li Q; Li Y; Chen J; Gao F; Jin B; Rossi A; Adachi H; Guerrera F; Husain H; Xu Y; Wang M
Transl Lung Cancer Res; 2023 Nov; 12(11):2229-2244. PubMed ID: 38090527
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study.
Zhou C; Wang Z; Fu C; Tao H; Liu C
Ann Transl Med; 2023 Feb; 11(3):157. PubMed ID: 36846007
[TBL] [Abstract][Full Text] [Related]
8. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status.
Xu H; Chen H; Kong J; Zhang Y; Liu S; Yang G; Yang L; Wang Y
Ann Transl Med; 2021 Jun; 9(11):937. PubMed ID: 34350252
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib in NSCLC: Real-World Data From New Zealand.
So YJ; Fraser A; Rivalland G; McKeage M; Sullivan R; Cameron L
JTO Clin Res Rep; 2020 Jun; 1(2):100022. PubMed ID: 34589929
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT).
Addeo A; Hochmair M; Janzic U; Dudnik E; Charpidou A; Płużański A; Ciuleanu T; Donev IS; Elbaz J; Aarøe J; Ott R; Peled N
Ther Adv Med Oncol; 2021; 13():17588359211059874. PubMed ID: 35173817
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
[TBL] [Abstract][Full Text] [Related]
13. Impact of
Igawa S; Ono T; Kasajima M; Ishihara M; Hiyoshi Y; Kusuhara S; Nishinarita N; Fukui T; Kubota M; Sasaki J; Hisashi M; Yokoba M; Katagiri M; Naoki K
Cancer Manag Res; 2019; 11():4883-4892. PubMed ID: 31213907
[No Abstract] [Full Text] [Related]
14. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
Yoshimura A; Yamada T; Okura N; Takeda T; Hirose K; Kubota Y; Shiotsu S; Hiranuma O; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875919
[TBL] [Abstract][Full Text] [Related]
15.
Roeper J; Christopoulos P; Falk M; Heukamp LC; Tiemann M; Stenzinger A; Thomas M; Griesinger F
Transl Lung Cancer Res; 2022 Jan; 11(1):4-13. PubMed ID: 35242623
[TBL] [Abstract][Full Text] [Related]
16. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
18. Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Kato Y; Hosomi Y; Watanabe K; Yomota M; Kawai S; Okuma Y; Kubota K; Seike M; Gemma A; Okamura T
J Thorac Dis; 2019 Jun; 11(6):2350-2360. PubMed ID: 31372272
[TBL] [Abstract][Full Text] [Related]
19. Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis.
Chang N; Duan J; Wang L; Dong Z; Liu Z
Oncol Lett; 2020 Sep; 20(3):2266-2272. PubMed ID: 32782544
[TBL] [Abstract][Full Text] [Related]
20. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]